What's Happening?
Iterion Therapeutics, a clinical-stage biopharmaceutical company, has announced positive results from its Phase 1/2 study of tegavivint, a targeted therapy for advanced hepatocellular carcinoma (HCC) with Wnt-pathway activating mutations (WPAMs). The study,
presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated that tegavivint was well tolerated and showed significant clinical responses. In patients with WPAMs, the therapy achieved a 22% overall response rate and an 89% disease control rate, with a median progression-free survival of 8 months. The study involved 40 patients, most of whom had previously undergone multiple lines of systemic therapy. Tegavivint works by inhibiting the Wnt/b-catenin signaling pathway, crucial for tumor growth and survival.
Why It's Important?
The development of tegavivint is significant as it addresses a critical unmet need for targeted therapies in patients with advanced HCC harboring Wnt-pathway mutations. These mutations are present in approximately 40% of advanced HCC cases, and no approved targeted therapies currently exist for this genetic profile. The promising results from Iterion's study suggest that tegavivint could become a novel treatment option, potentially improving outcomes for a genetically defined patient population. This advancement could also pave the way for further research and development of therapies targeting Wnt-driven cancers, impacting the broader oncology field.
What's Next?
Following the positive results, Iterion Therapeutics plans to continue the clinical development of tegavivint, focusing on its application in other Wnt-driven cancers, such as metastatic colorectal cancer and pediatric osteosarcoma. The company aims to expand its clinical trials to further validate the efficacy and safety of tegavivint in these additional cancer types. Iterion's ongoing research and development efforts are supported by significant funding from the Cancer Prevention and Research Institute of Texas, which will aid in advancing their proprietary Wnt/b-catenin platform.
